The Commonwealth Serum Laboratories was established in Australia in 1916.
At CSL, Corporate Responsibility is about conducting our business ethically.
We offer the broadest range of quality plasma-derived and recombinant therapies in the industry.
Seqirus opened in 2015 and is the second largest influenza company in the world.
Innovation has been in the DNA of CSL since our beginning in 1916
Our product portfolio focuses on innovation in new products
Help us deliver on our promise to save lives and protect the health of people.
Diversity and inclusion are top priorities for CSL.
View our ASX announcements
Visit this page to see all of our current news releases
CSL Extends Reach of Global Research Acceleration Initiative with Freshly Inked Partnerships to Fast-Track Research Programs
Bernadette Murdoch, an experienced Australian and global corporate affairs and communications leader across multiple industri…
MARBURG, GERMANY The new facility, once fully open later this calendar year, will be CSL’s largest R&D site under one roof, …
CSL is on track to file for regulatory approvals at end of current fiscal year and will present full data set at an upcoming …
CSL advances its vision for a more sustainable future by setting new, tangible targets for carbon emissions reductions
Global biotech leader CSL today announced that all business units will be united as one family under the CSL global brand.
CSL continues to provide medicines to patients around the world.
Statement attributable to Greg Boss, Executive Vice President - Legal, and CSL Limited Group General Counsel.
CSL ranked fourth on the Health Industry list, from a total of more than 750 organisations nominated in all sectors across Au…
Popular search terms:
Americas
Asia Pacific
MIddle East
Europe
Middle East
